Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
ESPR Quote, Financials, Valuation and Earnings
Last price:
$2.44
Seasonality move
:
-8.92%
Day range:
$2.57 - $2.73
52-week range:
$0.69 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.35x
P/B ratio:
--
Volume:
6.4M
Avg. volume:
4.3M
1-year change:
67.1%
Market cap:
$590.5M
Revenue:
$403.1M
EPS (TTM):
-$0.21
Analysts' Opinion
-
Consensus RatingEsperion Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.87, Esperion Therapeutics, Inc. has an estimated upside of 178.08% from its current price of $2.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.78 representing 27.94% downside risk from its current price of $2.59.
Fair Value
-
According to the consensus of 3 analysts, Esperion Therapeutics, Inc. has 178.08% upside to fair value with a price target of $6.87 per share.
ESPR vs. S&P 500
-
Over the past 5 trading days, Esperion Therapeutics, Inc. has underperformed the S&P 500 by -11.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Esperion Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Esperion Therapeutics, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Esperion Therapeutics, Inc. reported revenues of $168.4M.
Earnings Growth
-
Esperion Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Esperion Therapeutics, Inc. reported earnings per share of $0.22.
Enterprise value:
970.6M
EV / Invested capital:
3.95x
Price / LTM sales:
1.35x
EV / EBIT:
16.10x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-74.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
16.08x
Gross Profit (TTM):
$273.9M
Return On Assets:
-5.01%
Net Income Margin (TTM):
-5.63%
Return On Equity:
--
Return On Invested Capital:
-12.19%
Operating Margin:
50.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $116.3M | $332.3M | $403.1M | $69.1M | $168.4M | |
| Gross Profit | $72.9M | $263.7M | $273.9M | $43.5M | $140.6M | |
| Operating Income | -$142.5M | $54.4M | $60.3M | -$4.4M | $85.2M | |
| EBITDA | -$142.3M | $54.5M | $60.4M | -$4.4M | $85.3M | |
| Diluted EPS | -$2.11 | -$0.27 | -$0.21 | -$0.11 | $0.22 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $329M | $246.7M | $201.1M | $338M | $462.6M | |
| Total Assets | $381.6M | $247.9M | $205.8M | $345.3M | $883.7M | |
| Current Liabilities | $73.4M | $92.3M | $156.2M | $246.2M | $300.8M | |
| Total Liabilities | $578.5M | $571.7M | $660.8M | $734.1M | $1.2B | |
| Total Equity | -$196.9M | -$323.8M | -$455M | -$388.7M | -$302M | |
| Total Debt | $515.8M | $504.2M | $539.4M | $588.5M | $545.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$135.5M | -$23.7M | -$13.1M | -$35M | $45.2M | |
| Cash From Investing | $42.5M | -$317K | -- | -- | -- | |
| Cash From Financing | $50.5M | $86.5M | $36.2M | $35M | $30.2M | |
| Free Cash Flow | -$135.5M | -$24M | -$13.1M | -$35M | $45.2M | |
ESPR
Sector
Market Cap
$590.5M
$25.3M
Price % of 52-Week High
59.16%
48.74%
Dividend Yield
0%
0%
Shareholder Yield
-10.01%
-1.64%
1-Year Price Total Return
62.5%
-19.12%
Beta (5-Year)
1.107
0.492
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.86
200-day SMA
Buy
Level
$2.56
Bollinger Bands (100)
Sell
Level
2.9 - 3.74
Chaikin Money Flow
Sell
Level
-20.2M
20-day SMA
Sell
Level
$3.20
Relative Strength Index (RSI14)
Sell
Level
32.33
ADX Line
Sell
Level
27.96
Williams %R
Buy
Level
-94.6429
50-day SMA
Sell
Level
$3.35
MACD (12, 26)
Buy
Level
0.16
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-25.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2238)
Sell
CA Score
(Annual)
Level (-4.6414)
Sell
Beneish M-Score
(Annual)
Level (39.8786)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (6.3534)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Stock Forecast FAQ
In the current month, ESPR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ESPR average analyst price target in the past 3 months is $6.87.
-
Where Will Esperion Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Esperion Therapeutics, Inc. share price will rise to $6.87 per share over the next 12 months.
-
What Do Analysts Say About Esperion Therapeutics, Inc.?
Analysts are divided on their view about Esperion Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Esperion Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.78.
-
What Is Esperion Therapeutics, Inc.'s Price Target?
The price target for Esperion Therapeutics, Inc. over the next 1-year time period is forecast to be $6.87 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ESPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Esperion Therapeutics, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ESPR?
You can purchase shares of Esperion Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Esperion Therapeutics, Inc. shares.
-
What Is The Esperion Therapeutics, Inc. Share Price Today?
Esperion Therapeutics, Inc. was last trading at $2.44 per share. This represents the most recent stock quote for Esperion Therapeutics, Inc.. Yesterday, Esperion Therapeutics, Inc. closed at $2.59 per share.
-
How To Buy Esperion Therapeutics, Inc. Stock Online?
In order to purchase Esperion Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ESPR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ESPR
Sector
P/E ratio
--
21.47x
PEG ratio
--
-0.01x
P/B ratio
--
1.74x
Price / LTM sales
1.35x
1.45x
Growth Metrics
ESPR
Sector
Revenue growth
143.73%
3.36%
Earnings growth
299.36%
11.93%
Revenue (5-year growth)
12.12%
6.25%
Earnings forecast
$0.28
-$0.20
Profitability
ESPR
Sector
Profitability FY 2025
$273.9M
$2.2M
Return on invested capital
-12.19%
-33.31%
Return on assets
-5.01%
-29.82%
Return on equity
--
-40.01%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
May
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
ESPR
Sector
Total cash
$167.9M
$24.9M
Short term investments
--
$23.2M
Total assets
$883.7M
$69.8M
Long term debt
$545.9M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
